> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Acadia NDA for Nuplazid
- URL: https://www.fdaweb.com/panel-to-discuss-acadia-nda-for-nuplazid/
- Published: 2016-02-01T12:00:00.000Z
- Updated: 2026-09-15T02:32:09.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5134628

*Federal Register* Notice: FDA’s Psychopharmacologic Drugs Advisory Committee will meet 3/29 from 8 a.m. to 5 p.m. at FDA’s White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committee will discuss the specific risk-benefit profile for an Acadia Pharmaceuticals NDA for Nuplazid (pimavanserin) 17 mg immediate-release, film-coated oral tablets, for the proposed treatment of psychosis associated with Parkinson’s disease. Contact **Kalyani Bhatt**, (301) 796-9001\. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-02-01/pdf/2016-01752.pdf?ref=fdaweb.com)